St. Jude Expects To Take More CRT Share From Guidant Than Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Guidant's share of the cardiac resynchronization therapy (CRT) market is more vulnerable than that of Medtronic, according to St. Jude Medical CFO John Heinmiller
You may also be interested in...
ICD Firms’ Investors See Promise In Coverage Expansion – MDDI Index
St. Jude Medical's potential to leverage expanded Medicare coverage of implantable cardioverter defibrillators, set for finalization by year-end, helped buoy the firm's stock price in the third quarter
ICD Firms’ Investors See Promise In Coverage Expansion – MDDI Index
St. Jude Medical's potential to leverage expanded Medicare coverage of implantable cardioverter defibrillators, set for finalization by year-end, helped buoy the firm's stock price in the third quarter
Guidant Awaits SPIRIT Trial Data For Clear Vision Of Future Stent Business
Feasibility data on the Multi-Link Vision cobalt-chromium, durable-polymer, everolimus-eluting stent will be key to predicting the stability of Guidant's DES technology platform in the post-Dollens era